|
Jun 27
|
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
|
|
Jun 24
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
|
|
Feb 14
|
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
|
|
Feb 10
|
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
|
|
Feb 10
|
Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company
|